{"filings":[{"id":582757,"accession_number":"0001193125-26-234571","cik":1285550,"company_name":"ClearPoint Neuro, Inc.","ticker":"CLPT","form_type":"8-K","filed_at":"2026-05-21T20:30:16+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"ClearPoint Neuro shareholders approve 1M share increase in 2013 incentive plan; board committees reappointed","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Shareholders approved 7th Amended 2013 Incentive Compensation Plan, increasing share pool by 1,000,000 shares to 7,806,250 total.","All seven director nominees elected with >96% votes for each: Burnett, Fallon, Fletcher, Johnson, Klein, Liau, Richards.","Ratification of Cherry Bekaert LLP as auditor: 19.3M for, 20K against; advisory executive compensation approved 8.8M for, 442K against.","Board committees reappointed: Audit (Fallon chair), Compensation (Johnson chair), Governance (Fletcher chair); Fletcher confirmed as Chairman.","Non-employee director annual award cap set at 60,000 shares per year under the amended plan."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":355226373.22,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":68009,"accession_number":"0001193125-26-221596","cik":1285550,"company_name":"ClearPoint Neuro, Inc.","ticker":"CLPT","form_type":"8-K","filed_at":"2026-05-13T20:05:34+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"ClearPoint Neuro Q1 revenue $12.1M (+43% YoY); guides FY2026 $52-56M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Record Q1 revenue of $12.1M; organic device growth 25% YoY; gross margin expanded to 64% from 60%.","Neurosurgery navigation revenue surged 80% to $5.9M, driven by IRRA flow and 3.0 software adoption.","Biologics & drug delivery revenue stable at $4.8M; over 60 active biopharma partners enrolled.","Cash and equivalents $35.6M at Mar 31, 2026; expects cash burn to reduce in H2 2026 from cost synergies.","FDA cleared Velocity Alpha drill used in first clinical procedure; Health Canada MDL license obtained."],"consensus_eps_estimate":-0.2652,"consensus_eps_actual":-0.32,"consensus_revenue_estimate":null,"consensus_revenue_actual":12128000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":355226373.22,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":102339,"accession_number":"0001193125-26-110780","cik":1285550,"company_name":"ClearPoint Neuro, Inc.","ticker":"CLPT","form_type":"8-K","filed_at":"2026-03-17T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"ClearPoint Neuro reports Q4 revenue $10.4M (+34% YoY); FY 2025 revenue $37.0M (+18%); guides FY 2026 $52-56M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2025 revenue $10.4M including $1.2M from recent IRRAS acquisition; organic growth 19% YoY.","Full-year 2025 revenue $37.0M, 11th consecutive year of growth; 14% organic YoY increase.","2026 revenue guidance $52-56M, reflecting expected double-digit growth across all four product segments.","Completed IRRAS acquisition in Nov 2025, adding neurocritical care line and $20M additional financing from Oberland Capital.","Cash and equivalents $45.9M at Dec 31, 2025, up from $20.1M a year ago."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":355226373.22,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":102336,"accession_number":"0001193125-26-039470","cik":1285550,"company_name":"ClearPoint Neuro, Inc.","ticker":"CLPT","form_type":"8-K/A","filed_at":"2026-02-05T23:59:59+00:00","items":["9.01"],"status":"ready","headline":"ClearPoint Neuro files financials for acquired IRRAS; IRRAS cash from ops -$11.4M in 2024","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["IRRAS 2024 operating cash outflow $11.4M; accumulated deficit $105.3M.","Gross accounts receivable $1.67M with $22.5K credit loss allowance.","Convertible notes of $6.33M at 5% interest; fair value adjustment recorded $219.6K expense."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":355226373.22,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":102338,"accession_number":"0001193125-26-009867","cik":1285550,"company_name":"ClearPoint Neuro, Inc.","ticker":"CLPT","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"ClearPoint Neuro Q4 2025 prelim revenue $10.4M (+20% YoY); FY2026 guidance $54-60M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2025 preliminary unaudited revenue ~$10.4M, 20% comparable sales growth over Q4 2024, excluding recent IRRA flow acquisition.","Full year 2025 preliminary revenue ~$37M.","FY2026 revenue guided at $54-60M, driven by organic growth and IRRA flow product integration.","Q4 segment growth: functional neurosurgery disposables +23%, biologics/drug delivery +26%.","Preliminary results subject to revision; audited results expected later in Q1 2026."],"consensus_eps_estimate":-0.204,"consensus_eps_actual":-0.9,"consensus_revenue_estimate":null,"consensus_revenue_actual":36971000.0,"consensus_period":"2025-FY","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":355226373.22,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":102337,"accession_number":"0001193125-26-001581","cik":1285550,"company_name":"ClearPoint Neuro, Inc.","ticker":"CLPT","form_type":"8-K","filed_at":"2026-01-05T23:59:59+00:00","items":["1.01","2.03"],"status":"ready","headline":"ClearPoint Neuro enters consent for Swedish subsidiary reorganization under note purchase agreement","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Consent dated Dec 29, 2025 with TPC Investments III LP (Oberland affiliate) under the May 12, 2025 Note Purchase Agreement.","Company to undertake internal reorganization of IRRAS AB (Swedish sub) and transfer IRRAS USA equity by Jan 15, 2026.","Actions aim to qualify IRRAS AB as an \"Immaterial Foreign Subsidiary\" under the agreement.","Consent does not modify any material economic terms of the Note Purchase Agreement or the Third Sale of $20M notes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":355226373.22,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":118615,"accession_number":"0001193125-25-290003","cik":1285550,"company_name":"ClearPoint Neuro, Inc.","ticker":"CLPT","form_type":"8-K","filed_at":"2025-11-20T23:59:59+00:00","items":["1.01","2.01","3.02","7.01","9.01"],"status":"ready","headline":"ClearPoint Neuro completes acquisition of IRRAS for $5M cash + 1.325M shares","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Acquisition closed Nov 20, 2025; IRRAS shareholders received $5M cash and 1.325M CLPT shares.","Earnout consideration: 25% of net sales of certain IRRAS products above thresholds over three one-year periods.","IRRAS brings IRRA flow fluid-exchange system for intracranial bleeding, 50+ active customers, and commercial team.","ClearPoint Neuro expects expanded presence in neurocritical care and enhanced commercial scale from the deal."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":355226373.22,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":118614,"accession_number":"0001193125-25-270019","cik":1285550,"company_name":"ClearPoint Neuro, Inc.","ticker":"CLPT","form_type":"8-K","filed_at":"2025-11-06T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"ClearPoint Neuro Q3 rev $8.9M (+9% YoY); narrows FY25 guide $36-38M; acquires IRRAS","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 revenue $8.9M, up 9% YoY; cash $38.2M as of Sept 30, 2025.","FY2025 revenue guidance narrowed to $36M-$38M; combined 2026 with IRRAS expected $54M-$60M.","Signed agreement to acquire IRRAS Holdings; no purchase price disclosed.","New CAL preclinical facility operational; FDA 510(k) clearance for 1.5T PRISM Laser Therapy.","Active biopharma partners >60; plan to activate 35-40 specialized centers for cell/gene therapy."],"consensus_eps_estimate":-0.204,"consensus_eps_actual":-0.63,"consensus_revenue_estimate":null,"consensus_revenue_actual":26561000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":355226373.22,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":118613,"accession_number":"0001193125-25-269992","cik":1285550,"company_name":"ClearPoint Neuro, Inc.","ticker":"CLPT","form_type":"8-K","filed_at":"2025-11-06T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"ClearPoint Neuro to acquire IRRAS for $5M cash + 1.325M shares; combined 2026 rev $54-60M","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Total consideration: $5M cash plus 1.325M ClearPoint shares; earnout of 25% of net IRRA flow sales above thresholds.","IRRAS's IRRA flow catheter addresses ~400K US procedures/yr, targeting a $0.5B global intracranial bleeding market.","IRRAS has >50 active customers and 83% growth in first 9 months of 2025 to ~$9M revenue run-rate.","Combined entity expected to have 40+ additional commercial professionals; 2026 revenue guidance $54M-$60M.","Transaction approved by both boards; closing conditions include IRRAS stockholder approval and Nasdaq Stockholm delisting by Dec 31, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":355226373.22,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":135101,"accession_number":"0001285550-25-000010","cik":1285550,"company_name":"ClearPoint Neuro, Inc.","ticker":"CLPT","form_type":"8-K","filed_at":"2025-08-12T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"ClearPoint Neuro Q2 revenue record $9.2M (+17% YoY); secures up to $105M note financing","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Record Q2 revenue $9.2M, up 17% YoY; neurosurgery segment revenue up 33% to $3.4M.","Operating expenses $11.2M (+16% YoY); gross margin 60% vs 63% on higher inventory reserves.","Entered $105M note financing with Oberland Capital; $30M funded at closing plus $3.5M stock purchase.","Cash and equivalents $41.5M at June 30, compared to $20.1M at year-end 2024.","Full-year 2025 revenue outlook reaffirmed at $36.0M-$41.0M."],"consensus_eps_estimate":-0.204,"consensus_eps_actual":-0.42,"consensus_revenue_estimate":null,"consensus_revenue_actual":17700000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":355226373.22,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":152073,"accession_number":"0001683168-25-004550","cik":1285550,"company_name":"ClearPoint Neuro, Inc.","ticker":"CLPT","form_type":"8-K","filed_at":"2025-06-17T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"ClearPoint Neuro signs 132-month lease for ~30,171 sq ft in San Diego life science building","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Lease with BRE-BMR SCD LLC for office, R&D, and lab space at $5.95/sq ft initial monthly base rent.","Phased occupancy: Phase 1 basement by June 13, 2025; Phase 2 basement by Dec 19, 2025; first floor by July 1, 2026.","Lease term 132 months from last occupancy date with one five-year extension option; base rent escalates 3% annually.","Tenant must provide a $179,517.45 letter of credit as security; free rent periods structured per phase.","Company expanding existing Solana Beach HQ into larger San Diego facility for growth."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":355226373.22,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":152072,"accession_number":"0000950170-25-076992","cik":1285550,"company_name":"ClearPoint Neuro, Inc.","ticker":"CLPT","form_type":"8-K","filed_at":"2025-05-23T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"ClearPoint Neuro stockholders approve all six proposals at 2025 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All eight director nominees elected; Joseph M. Burnett received 9,980,965 votes for.","Cherry Bekaert LLP ratified as auditor for FY 2025 with 18,622,225 votes for.","Say-on-pay passed advisory vote; frequency set to one year (9,698,448 votes).","Stockholders approved the Amended and Restated 2021 Employee Stock Purchase Plan.","Sixth Amended and Restated 2013 Incentive Compensation Plan approved (8,440,784 for)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":355226373.22,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":152071,"accession_number":"0000950170-25-074397","cik":1285550,"company_name":"ClearPoint Neuro, Inc.","ticker":"CLPT","form_type":"8-K","filed_at":"2025-05-19T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"ClearPoint Neuro amends director compensation plan with updated cash retainers","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board chair annual retainer increased to $75,000; other members to $45,000 (effective July 1, 2025).","Committee chair retainers: Audit $20,000, Compensation $15,000, Governance $12,000.","Committee member retainers: Audit $10,000, Compensation $7,500, Governance $7,500.","New director one-time RSU grant valued at $150,000; annual RSU grant also $150,000.","Plan last amended May 22, 2023; Board approved latest revision on May 18, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":355226373.22,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":152070,"accession_number":"0000950170-25-070346","cik":1285550,"company_name":"ClearPoint Neuro, Inc.","ticker":"CLPT","form_type":"8-K","filed_at":"2025-05-13T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"ClearPoint Neuro reports record Q1 revenue $8.5M, consumables up 104% YoY","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 revenue $8.5M (record), up 11% YoY; consumable product revenue grew 104% to $5.5M.","Neurosurgery navigation therapy revenue up 70% to $3.3M; biologics & drug delivery revenue up 9% to $4.7M.","Gross margin 60% (vs 59%); opEx up 29% to $11.3M on higher R&D and headcount.","Cash $12.4M at Mar 31 (down from $20.1M Dec 2024); credit facility secured with Oberland Capital.","FY 2025 revenue guidance reaffirmed at $36M-$41M; FDA clearance for ClearPoint 3.0 software."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.22,"consensus_revenue_estimate":null,"consensus_revenue_actual":8485000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":355226373.22,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":152069,"accession_number":"0000950170-25-069175","cik":1285550,"company_name":"ClearPoint Neuro, Inc.","ticker":"CLPT","form_type":"8-K","filed_at":"2025-05-12T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"ClearPoint Neuro secures up to $110M from Oberland Capital with $33.5M funded at closing","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Enters note agreement for up to $105M; $30M funded at closing, up to $25M optional second tranche, up to $50M third tranche.","Issues 275,808 shares at $12.69 in registered direct offering for $3.5M gross proceeds.","Notes bear interest at Term SOFR + 3.95% (min 8.25%, cap 9.50%); first six quarters 50% PIK interest.","Proceeds for general corporate purposes; no financial covenants; secured by substantially all assets including IP."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":355226373.22,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":170894,"accession_number":"0000950170-25-027716","cik":1285550,"company_name":"ClearPoint Neuro, Inc.","ticker":"CLPT","form_type":"8-K","filed_at":"2025-02-26T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"ClearPoint Neuro reports record FY2024 revenue $31.4M, 31% growth; guides FY2025 $36-41M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FY 2024 revenue $31.4M (+31% YoY); Q4 revenue $7.8M (+14% YoY).","Gross margin improved to 61% from 57%; operating expenses rose 8% to $38.9M.","Repaid $10M convertible note; cash $20.1M; operational cash burn down 35% to $9.0M.","2025 revenue guidance $36-41M, implying 15-31% growth.","Biologics/drug delivery revenue up 76% to $18.6M; added 25 new centers in 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.7,"consensus_revenue_estimate":null,"consensus_revenue_actual":31390000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":355226373.22,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":187862,"accession_number":"0001285550-24-000120","cik":1285550,"company_name":"ClearPoint Neuro, Inc.","ticker":"CLPT","form_type":"8-K","filed_at":"2024-11-07T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"ClearPoint Neuro Q3 revenue $8.1M (+41% YoY); FY guidance reaffirmed","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Record quarterly revenue of $8.1M, up 41% YoY; navigation & device revenue $2.9M (+49%).","Biologics & drug delivery revenue $4.4M (+27%); capital equipment revenue $0.8M (+133%).","Gross margin 60% vs 57% YoY; operating expenses $10M (up from $8.2M) on higher personnel and development costs.","Cash $21.6M; fully repaid $10M convertible note leaving no debt; operational cash burn cut 33% to $1.2M.","Activated 5 new centers in Q3 (19 YTD, ~3x historic rate); FY 2024 revenue outlook held at $30-33M."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.5,"consensus_revenue_estimate":null,"consensus_revenue_actual":23619000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":355226373.22,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":187861,"accession_number":"0001104659-24-115372","cik":1285550,"company_name":"ClearPoint Neuro, Inc.","ticker":"CLPT","form_type":"8-K","filed_at":"2024-11-07T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"ClearPoint Neuro enters $50M ATM equity offering with Stifel","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["ATM agreement with Stifel allows sale of up to $50M in common stock from time to time.","Agent commission of 3.0% of gross sales proceeds; shares sold via Nasdaq Capital Market.","Prospectus supplement filed Nov 7, 2024; registration statement effective since Nov 20, 2023.","Company not obligated to sell any shares; may suspend or terminate offering at any time."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":355226373.22,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":204386,"accession_number":"0001285550-24-000107","cik":1285550,"company_name":"ClearPoint Neuro, Inc.","ticker":"CLPT","form_type":"8-K","filed_at":"2024-08-26T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"ClearPoint Neuro repays $10M convertible note early, eliminates all debt","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["On Aug 23, 2024, fully repaid $10M convertible note held by PTC Therapeutics (orig. maturity Jan 2025).","Note was issued in Jan 2020; early repayment removes all debt from ClearPoint's balance sheet.","CEO says repayment avoids additional dilution and reflects confidence in the business.","PTC continues to support ClearPoint for Upstaza BLA submission to FDA for AADC deficiency."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":355226373.22,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":204385,"accession_number":"0001285550-24-000097","cik":1285550,"company_name":"ClearPoint Neuro, Inc.","ticker":"CLPT","form_type":"8-K","filed_at":"2024-08-07T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"ClearPoint Neuro Q2 revenue $7.9M (+32% YoY); raises FY2024 guidance to $30-33M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Record quarterly revenue of $7.9M, up 32% YoY; product revenue more than doubled to $4.9M.","Gross margin improved to 63% from 53% a year ago; operating cash burn reduced 47% to $2.7M.","Raised FY2024 revenue guidance to $30-33M from prior; cash position $32.8M after public offering.","Activated 6 new global centers in Q2 (14 YTD); SmartFrame OR and Prism Laser Therapy launched.","Seven pharma partners received expedited FDA review; SmartFlow Cannula approved in Taiwan."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.32,"consensus_revenue_estimate":null,"consensus_revenue_actual":15497000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.78,"calibrated_materiality_score":0.78,"market_cap_usd":355226373.22,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":221145,"accession_number":"0001285550-24-000061","cik":1285550,"company_name":"ClearPoint Neuro, Inc.","ticker":"CLPT","form_type":"8-K","filed_at":"2024-05-16T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"ClearPoint Neuro stockholders re-elect eight directors, approve incentive plan","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All eight director nominees elected with over 11.6M votes for each; broker non-votes 6.8M.","Ratification of Cherry Bekaert as auditor: 18.9M for, 68.6K against, 21K abstain.","Advisory say-on-pay approved: 11.1M for, 629.5K against, 431.8K abstain; broker non-votes 6.8M.","Stockholders approved Fifth Amended and Restated 2013 Incentive Compensation Plan: 11.0M for, 699.5K against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":355226373.22,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":221144,"accession_number":"0001285550-24-000049","cik":1285550,"company_name":"ClearPoint Neuro, Inc.","ticker":"CLPT","form_type":"8-K","filed_at":"2024-05-07T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"ClearPoint Neuro Q1 revenue $7.6M (+41% YoY); biologics revenue $4.3M (+61%); cash burn down 32%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Record quarterly revenue of $7.6M, up 41% YoY; biologics/drug delivery revenue up 61% to $4.3M.","Capital equipment sales surged 255% to $1.4M; SmartFrame OR received 510(k) clearance and first clinical cases performed.","Activated 8 new hospital sites in Q1, a company record, bringing total active sites to over 80.","Operational cash burn reduced 32% to $3.8M; cash and equivalents totaled $35.4M after $16.2M public offering.","Reaffirmed FY2024 revenue outlook of $28M-$32M; first-ever neuro gene therapy BLA submitted by partner PTC Therapeutics."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.16,"consensus_revenue_estimate":null,"consensus_revenue_actual":7639000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":355226373.22,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":240728,"accession_number":"0001285550-24-000030","cik":1285550,"company_name":"ClearPoint Neuro, Inc.","ticker":"CLPT","form_type":"8-K","filed_at":"2024-03-12T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"ClearPoint Neuro Q4 revenue $6.8M (+32% YoY); FY2023 revenue $24M (+17%); reaffirms 2024 guidance $28M-$32M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2023 revenue $6.8M, up 32% YoY; full-year revenue $24.0M, up 17% YoY.","Biologics & drug delivery revenue $13.6M in 2023, +49% YoY; gross margin 57% (down from 66%).","Cash & equivalents $23.1M at Dec 31; Q4 cash burn reduced to $1.2M.","Reaffirmed 2024 revenue guidance $28M-$32M; early 2024 milestones include 6 new hospitals, FDA clearance, ~$15M equity offering.","Operating expenses $36.1M in 2023 (up from $29.9M), driven by higher headcount and share-based compensation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":355226373.22,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":240727,"accession_number":"0001104659-24-029960","cik":1285550,"company_name":"ClearPoint Neuro, Inc.","ticker":"CLPT","form_type":"8-K","filed_at":"2024-03-01T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"ClearPoint Neuro prices $15M public offering of 2.3M shares at $6.50","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering of 2,307,694 shares of common stock at $6.50 per share; underwriters have 30-day option for 346,154 additional shares.","Net proceeds expected to be approximately $14.0 million, or $16.2 million if over-allotment option fully exercised.","Proceeds to be used for general corporate purposes, including R&D, potential acquisitions, investments, or debt repayment.","Offering expected to close on or about March 4, 2024; Lake Street Capital Markets is lead underwriter."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":355226373.22,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}